Oculis Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCS research report →
About the company
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease.
- CEO
- Riad Sherif
- IPO
- 2021
- Employees
- 49
- HQ
- Zug, CH
Price Chart
- Market Cap
- $807.23M
- P/E
- -6.55
- P/S
- 1286.16
- P/B
- 3.41
- EV/EBITDA
- -6.23
- Div Yield
- 0.00%
- Gross Margin
- -2889.37%
- Op Margin
- -16740.95%
- Net Margin
- -18861.29%
- ROE
- -57.09%
- ROIC
- -42.07%
- Revenue
- $0 · -100.00%
- Net Income
- $-94,508,181 · -10.18%
- EPS
- $-1.81 · 14.62%
- Op Income
- $-79,145,361
- FCF YoY
- -30.97%
- 52W High
- $34.48
- 52W Low
- $10.52
- 50D MA
- $21.07
- 200D MA
- $22.61
- Beta
- 0.20
- Avg Volume
- 706.96K
Get TickerSpark's AI analysis on OCS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our OCS coverage
Recent articles, reports, and earnings notes.
No research on OCS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCS report →Similar companies
Peers in the same neighborhood.